Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/307% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Regeneron Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.60B, up 17.0% year over year. For fiscal 2025 it was $5.85B, up 14.0% from the year before. Over ten years it grew 13.7% a year on average. The highest annual figure on record is $5.85B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.85B | +14.0% |
| FY2024 | Dec 31, 2024 | $5.13B | +15.6% |
| FY2023 | Dec 31, 2023 | $4.44B | +23.6% |
| FY2022 | Dec 31, 2022 | $3.59B | +25.6% |
| FY2021 | Dec 31, 2021 | $2.86B | +8.1% |
| FY2020 | Dec 31, 2020 | $2.65B | +8.0% |
| FY2019 | Dec 31, 2019 | $2.45B | +66.8% |
| FY2018 | Dec 31, 2018 | $1.47B | -29.2% |
| FY2017 | Dec 31, 2017 | $2.08B | +1.1% |
| FY2016 | Dec 31, 2016 | $2.05B | +26.6% |
| FY2015 | Dec 31, 2015 | $1.62B | +27.5% |
| FY2014 | Dec 31, 2014 | $1.27B | +47.8% |
| FY2013 | Dec 31, 2013 | $859.95M | +37.5% |
| FY2012 | Dec 31, 2012 | $625.55M | +18.1% |
| FY2011 | Dec 31, 2011 | $529.51M | +8.2% |
| FY2010 | Dec 31, 2010 | $489.25M | +22.7% |
| FY2009 | Dec 31, 2009 | $398.76M | +45.1% |
| FY2008 | Dec 31, 2008 | $274.90M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.79B | +21.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.63B | +14.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.54B | +16.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.63B | +15.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.48B | +16.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.42B | +18.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.33B | +6.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.41B | +20.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.27B | +18.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.20B | +10.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.25B | +13.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.18B | +12.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.08B | +18.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.09B | +36.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.10B | +30.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.04B | +41.4% |
| Q3 FY2022 | Sep 30, 2022 | $911.30M | +37.0% |
| Q2 FY2022 | Jun 30, 2022 | $794.30M | +11.2% |
| Q1 FY2022 | Mar 31, 2022 | $843.80M | +13.6% |
| Q4 FY2021 | Dec 31, 2021 | $737.60M | +12.4% |
| Q3 FY2021 | Sep 30, 2021 | $665.40M | -2.8% |
| Q2 FY2021 | Jun 30, 2021 | $714.20M | -1.1% |
| Q1 FY2021 | Mar 31, 2021 | $742.90M | +27.2% |
| Q4 FY2020 | Dec 31, 2020 | $656.50M | +18.8% |
| Q3 FY2020 | Sep 30, 2020 | $684.60M | +30.2% |
| Q2 FY2020 | Jun 30, 2020 | $722.00M | -18.5% |
| Q1 FY2020 | Mar 31, 2020 | $583.90M | +20.1% |
| Q4 FY2019 | Dec 31, 2019 | $552.40M | -8.1% |
| Q3 FY2019 | Sep 30, 2019 | $526.00M | -5.6% |
| Q2 FY2019 | Jun 30, 2019 | $885.50M | +67.3% |
| Q1 FY2019 | Mar 31, 2019 | $486.10M | -2.5% |
| Q4 FY2018 | Dec 31, 2018 | $601.30M | +13.9% |
| Q3 FY2018 | Sep 30, 2018 | $557.00M | +5.1% |
| Q2 FY2018 | Jun 30, 2018 | $529.30M | +3.8% |
| Q1 FY2018 | Mar 31, 2018 | $498.60M | -1.7% |
| Q4 FY2017 | Dec 31, 2017 | $527.94M | +10.2% |
| Q3 FY2017 | Sep 30, 2017 | $529.75M | – |
| Q2 FY2017 | Jun 30, 2017 | $509.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $507.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $479.21M | – |
See a number that looks wrong?